Mexiletine
Orphan DrugFDA Approved
Contents
Description
Mexiletine is a sodium channel blocker originally developed as an antiarrhythmic agent. It has been repurposed for treating neuropathic pain and primary erythermalgia by stabilizing hyperexcitable nerve membranes. It reduces the frequency and severity of painful burning episodes in erythermalgia patients.
Indications & Therapeutic Use
primary erythermalgia, neuropathic pain, myotonia, ventricular arrhythmias
Linked Diseases:
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Mexiletine — GNH India
24 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Dopital
EU
Mexiletine 200mg
200mgcapsuleCanada
MEXILETINE HCL
200mgcapsuleUSA
Mexiletine Hydrochloride
150 mg/1capsuleUSA
Mexiletine Hydrochloride Clinigen Healthcare
EU
MINT-MEXILETINE
100 MGcapsuleCANADA
Ritalmex
EU
TEVA-MEXILETINE
100 MGcapsuleCANADA
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Mexiletine
| Generic Name | mexiletine |
| Brands | 1 brand available |
| Active Ingredient | mexiletine hydrochloride |
| Drug Class | primary erythermalgia |
| Manufacturer | Lupin Pharmaceuticals |
| Dosage Forms | oral capsule 150mg, 200mg, 250mg |
| Medical Code | C01BB02 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT02045667 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes